Research in the Sleckman Lab discovers novel cellular pathways that maintain the fundamental integrity of the mammalian genome through the repair of damaged DNA. The lab is primarily focused on how genomic DNA double-stranded breaks (DSBs) are generated and repaired. These studies are particularly focused on cancer and how the corruption of DSB repair pathways in cancer cells leads to genomic lesions and a genomic evolution that improves cancer cell fitness. It is these pathways that will be important targets for the development of novel cancer therapeutics. The lab is currently employing cell-based cutting-edge CRISPR-Cas9 screening approaches to identify novel DNA DSB repair pathways and their components. In addition, we develop and utilize mouse models to establish the role of these pathways in maintaining genome stability in normal and cancer cells in vivo. The Sleckman lab is at Weill Cornell Medicine in New York City and is joint with the lab of Dr. Jessica Tyler who focuses on the role of chromatin dynamics and epigenetics in DNA damage responses and repair.
The mission of the Sleckman is to identify novel DNA damage responses pathways and to understand how these pathways effect normal immune responses and, when corrupted, how they lead to genome instability and lymphoid malignancies.